Tag Archives: antibody dependent cell-mediated cytotoxicity

Gastric Cancer Monoclonal Antibody Against Specific Target Shows Promise in Phase 2b Study

In a phase II randomized trial, adding IMAB362 to standard chemotherapy increased progression-free survival (PFS) and overall survival (OS) by about 50% compared with the standard treatment alone. Continue reading

Early Cancer Detection Company, Grail, Led by Former Google VP – Ashley P. Angelo, Contributor

Healthcare firm Grail, which has been formed by the gene sequencing company Illumina, named Jeff Huber, former Google X Senior Vice President, as its CEO in February. With Huber’s experience in developing large-scale data, Grail hopes to improve gene sequencing technology used in blood tests for early detection of cancer in asymptomatic patients so that immunotherapeutic strategies, as opposed to toxic chemotherapy, can be employed with the goal of curing cancer. Continue reading

Enhanced ADCC technologies to improve cancer cytotoxicity

Antibody Dependent Cell-Mediated Cytotoxicity (ADCC) is a process by which the Fab (variable region) of antibodies, produced by B-cells, first bind to antigens on target cells (cancer), and their Fc (constant regions) then bind white cells (macrophages, granulocytes, and NK – natural killer cells), which destroy the target cells.  The antibodies opsonize the target and then attract white cells to destroy the target. Continue reading